We are live on ! Find out more
FNCH

Finch Therapeutics Group, Inc. Common Stock

Delisted

FNCH was delisted on the 24th of May, 2024.

33 hedge funds and large institutions have $3.75M invested in Finch Therapeutics Group, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 10 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

18% less funds holding

Funds holding: 4033 (-7)

18% less capital invested

Capital invested by funds: $4.6M → $3.75M (-$848K)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

70% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 10

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 7

Holders
33
Holders Change
-7
Holders Change %
-17.5%
% of All Funds
0.53%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
Increased
3
Reduced
10
Closed
7
Calls
Puts
Net Calls
Net Calls Change

FNCH Hedge Fund Activity: Q1 2023 in Review

33 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Finch Therapeutics Group, Inc. Common Stock (FNCH) for Q1 2023, worth a combined $3.75M — down 18% from $4.6M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of FNCH and 0 opened new positions — a net loss of 7 holders — while 10 trimmed existing stakes and 3 added.

The largest buyer was Baupost Group, adding an estimated $442K. The largest seller was TRB Advisors, exiting entirely with an estimated $274K sold.

  • 33 institutional investors held Finch Therapeutics Group, Inc. Common Stock (FNCH) as of Q1 2023, down from 40 in Q4 2022.
  • Funds reported $3.75M of Finch Therapeutics Group, Inc. Common Stock stock for Q1 2023, down 18% quarter-over-quarter.
  • 0 funds opened new Finch Therapeutics Group, Inc. Common Stock positions in Q1 2023 and 7 closed out, a net change of -7 holders.
  • The largest Finch Therapeutics Group, Inc. Common Stock buyer in Q1 2023 was Baupost Group, an estimated $442K added.
  • The largest Finch Therapeutics Group, Inc. Common Stock seller in Q1 2023 was TRB Advisors, an estimated $274K sold.

Based on aggregated 13F filings for Q1 2023.